세계의 당뇨병 치료 및 진단 시장 규모는 2023년 1,022억 달러에서 예측기간 중 5.2%의 CAGR로 성장하여 2028년에는 1,320억 달러 규모로 성장할 것으로 예측됩니다.
치료제 부문은 2023년 593억 달러에서 4.0%의 CAGR로 성장하여 2028년에는 722억 달러 규모로 성장할 것으로 예측됩니다. 또한 당뇨병 모니터링 기기 및 부속품 부문은 2023년 250억 달러에서 6.4%의 CAGR로 성장하여 2028년에는 341억 달러 규모로 성장할 것으로 예측됩니다.
세계의 당뇨병 치료 및 진단 시장을 조사했으며, 시장 개요, 시장 영향요인 및 시장 기회 분석, 기술 개발 동향, 제품 파이프라인, 시장 규모 추정과 예측, 각종 부문·지역별 상세 분석, ESG 전개, 경쟁 상황, 주요 기업 개요 등을 정리했습니다.
목차
제1장 서론
제2장 요약과 하이라이트
제3장 시장 개요
- 당뇨병이란?
- 당뇨병 유형
- 1형 당뇨병
- 2형 당뇨병
- 임신성 당뇨병(GDM) 또는 임신중 고혈당
- 내당능이상(IGT) 및 공복시 혈당 이상(IFG)
- 당뇨병 역학
- 성별 분포
- 지역 차이
- 성장 촉진요인·시장의 발전
- 시장 성장 촉진요인
- 시장 성장 억제요인
제4장 세계의 당뇨병 치료제 시장
- 개요
- 항당뇨병제 분류·유형
- 당뇨병 주사제
- 경구 항당뇨병제(OAD)
- 특허 절벽
- 당뇨병 치료제의 최신 기술 진보·개발·제품 파이프라인
- 현재 제품 파이프라인
- 현재 연구 중인 기타 잠재 치료제
제5장 세계의 당뇨병 모니터링 기기 및 부속품 시장
- 개요
- 혈당 자가 모니터링(SMBG)
- SMBG 시장 구조
- 혈당 디바이스의 최신 기술 진보와 개발
- 연속 혈당 모니터링(CGM) 시스템
- CGM 시스템의 개발
제6장 세계의 당뇨병 약물전달 디바이스 시장
- 개요
- 인슐린 주사기
- 인슐린 주사기 사용의 이점
- 인슐린 주사기 사용의 단점
- 인슐린 주사기 최신 기술 진보와 개발
- 인슐린 투여 펜형 디바이스
- 일회용 인슐린 펜
- 재사용 가능 인슐린 펜
- 인슐린 투여 펜형 디바이스의 최신 기술 진보와 개발
- 인슐린 제트 인젝터
- 인슐린 제트 인젝터 사용의 이점
- 인슐린 제트 주사기 사용의 단점
- 외부 인슐린 펌프
- 인슐린 펌프의 이점
- 인슐린 펌프의 단점
- 인슐린 펌프 시스템의 최신 기술 진보와 개발
- 매립형 인슐린 펌프
- 클로즈드 루프 인공 췌장
- 바이오닉 췌장
- 인공 췌장(생리학적 접근법)
- 인슐린 흡입기
- 인슐린 흡입기의 이점
- 인슐린 흡입기의 단점
- 인슐린 흡입기 유형
- 인슐린 패치
- 경구 인슐린 투여
제7장 세계의 당뇨병 치료 및 진단 시장 : 최종사용자별
제8장 세계의 당뇨병 치료 및 진단 시장 : 지역별
- 개요
- 북미
- 미국
- 캐나다
- 유럽
- 독일
- 영국
- 프랑스
- 스페인
- 이탈리아
- 기타 유럽
- 아시아태평양
- 중국
- 인도
- 일본
- 호주
- 기타 아시아태평양
- 기타 지역
- 남미
- 중동 및 아프리카
제9장 당뇨병 치료 및 진단 시장 지속가능성 : ESG 관점
제10장 신기술
- 혈당 조절을 넘어선 환자 결과
- 디지털 헬스를 활용한 당뇨병 기술
- 경구 항당뇨병제로의 경향이 높아진다
- 의료의 액세스 용이성과 적정 가격에 대한 주목 상승
- 인공 췌장
제11장 시장의 M&A와 벤처 자금 조달 전망
- M&A 분석
- Lilly's에 의한 Protomer Technologies 인수
제12장 경쟁 상황
제13장 기업 개요
- 77 ELEKTRONIKA KFT.
- ABBOTT
- ALTUCELL
- ASCENSIA DIABETES CARE HOLDINGS AG.
- ASTRAZENECA
- B. BRAUN SE
- BIOCON
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- DANAHER
- DEXCOM INC.
- EMBECTA CORP.
- INSULET CORPORATION.
- JOHNSON & JOHNSON SERVICES INC.
- LIFESCAN IP HOLDINGS LLC
- LILLY
- MEDTRONIC
- MENARINI GROUP(A. MENARINI DIAGNOSTICS S.R.L)
- MERCK & CO. INC.
- MERCK KGAA
- NEXTCELL PHARMA AB
- NIPRO
- NOVA BIOMEDICAL
- NOVARTIS AG
- NOVO NORDISK A/S
- ROCHE(F. HOFFMANN-LA ROCHE LTD)
- SANOFI
- TAKEDA PHARMACEUTICAL COMPANY LIMITED.
- TANDEM DIABETES CARE INC.
- TERUMO CORPORATION
- YPSOMED AG
제14장 부록
KSM
Highlights:
The global market for diabetes therapeutics and diagnostics is estimated to increase from $102.2 billion in 2023 to reach $132.0 billion by 2028, at a compound annual growth rate (CAGR) of 5.2% from 2023 through 2028.
The global market for diabetes therapeutics is estimated to increase from $59.3 billion in 2023 to reach $72.2 billion by 2028, at a compound annual growth rate (CAGR) of 4.0% from 2023 through 2028.
The global market for diabetes monitoring devices and accessories is estimated to increase from $25.0 billion in 2023 to reach $34.1 billion by 2028, at a compound annual growth rate (CAGR) of 6.4% from 2023 through 2028.
Report Scope:
This report discusses the implications of the trends mentioned above in the context of the current size and growth of the diabetes market, in global terms and by the most important national markets. Companies in the relevant pharmaceutical and medical industries are discussed, with profiles of the leaders and an update on M&A activity. Five-year global sales forecasts are provided for the leading drug and device categories, and there are country-level breakdowns of the diabetes market.
Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the compound annual growth rate (CAGR) for the diabetes therapeutics and diagnostics market.
This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific and the Rest of the World. For market estimates, data is provided for 2022 as the base year, 2023 and forecast through year-end 2028.
Report Includes:
- 162 data tables and 63 additional tables
- An up-to-date overview and analysis of the global markets for diabetes therapeutics and diagnostics
- Analyses of the global market trends, with market revenue (sales figures) for 2020-2022, estimates for 2023, and projections of compound annual growth rates (CAGRs) through 2028
- Understanding of the upcoming market potential for AI in diabetic mellitus management with an emphasis on new products and solutions/platform technologies, and areas of focus to forecast this market into various segments and sub-segments
- Estimation of the actual market size and revenue forecast for the global diabetes therapeutics and diagnostics market, and corresponding market share analysis based on product type, end user, and geographical region
- In-depth information (facts and figures) on major market dynamics, opportunities and gaps estimating the demand, technology adaptations in diabetes care, industry developments, regulatory dynamics, and the COVID-19 impact on the progress of this market
- Identification of the companies best positioned to meet this demand owing to or in conjunction with their proprietary technologies, product launches, and other strategic advantages
- Review of key patent grants and patent applications on diabetes therapeutics and diagnostics, and emerging technologies and new developments in this market
- Analysis of the company competitive landscape based on their recent developments, financial performance, segmental revenues, and operational integration
- Company profiles of the leading global players, including Novo Nordisk, Sanofi S.A., Lilly, Takeda, Danaher Corp., and AstraZeneca
Table of Contents
Chapter 1 Introduction
- Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Study Goals and Objectives
- Reasons for Doing This Study
- What's New in This Report
- Scope of Report
- Information Sources
- Methodology
- Secondary Research
- Primary Interviews
- Geographic Breakdown
Chapter 2 Summary and Highlights
- Market Overview
- Significant Developments and Trends
Chapter 3 Market Overview
- What is Diabetes?
- Types of Diabetes
- Type 1 Diabetes
- Type 2 Diabetes
- Gestational Diabetes Mellitus (GDM) or Hyperglycemia in Pregnancy
- Impaired Glucose Tolerance (IGT) and Impaired Fasting Glucose (IFG)
- Epidemiology of Diabetes
- Gender Distribution
- Regional Disparities
- Market Factors Driving the Growth and Development of the Market
- Market Drivers
- Market Restraints
Chapter 4 Global Market for Diabetes Therapeutics
- Overview
- Classification and Types of Antidiabetic Medications
- Injectable Therapies for Diabetes
- Oral Antidiabetic Drugs (OADs)
- Facing the Patent Cliff
- Latest Technological Advances, Developments and Product Pipelines for Diabetic Medications
- Current Product Pipeline
- Other Potential Therapies Currently Under Investigation
Chapter 5 Global Market for Diabetes Monitoring Devices and Accessories
- Overview
- Self-Monitoring of Blood Glucose (SMBG)
- SMBG Market Structure
- Latest Technological Advances and Developments in Blood Glucose Devices
- Continuous Glucose Monitoring (CGM) Systems
- Development of CGM Systems
Chapter 6 Global Market for Diabetes Delivery Devices by Type
- Overview
- Insulin Syringes
- Advantages of Using Insulin Syringes
- Disadvantages of Using Insulin Syringes
- Latest Technological Advances and Developments in Insulin Syringes
- Insulin Delivery Pen Devices
- Disposable Insulin Pens
- Reusable Insulin Pens
- Latest Technological Advances and Developments in Insulin Delivery Pen Devices
- Insulin Jet Injectors
- Advantages of Using Insulin Jet Injectors
- Disadvantages of Using Insulin Jet Injectors
- External Insulin Pumps
- Advantages of Insulin Pumps
- Disadvantages of Insulin Pumps
- Latest Technological Advances and Developments in Insulin Pump Systems
- Implantable Insulin Pumps
- Closed-Loop Artificial Pancreas
- Bionic Pancreas
- Artificial Pancreas (the Physiological Approach)
- Insulin Inhalers
- Advantages of Insulin Inhalers
- Disadvantages of Insulin Inhalers
- Types of Insulin Inhalers
- Insulin Patches
- Oral Insulin Delivery
Chapter 7 Global Market for Diabetes Therapeutics and Diagnostics by End User
- Overview
- Hospitals and Clinics
- Diagnostic Centers
- Home Care Organizations
Chapter 8 Global Market for Diabetes Therapeutics and Diagnostics by Region
- Overview
- North America
- United States
- Canada
- Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific
- Rest of the World
- South America
- Middle East and Africa
Chapter 9 Sustainability in the Market for Diabetes Therapeutics and Diagnostics: An ESG Perspective
- Introduction
- Market for Diabetes Therapeutics and Diagnostics: ESG Performance Analysis
Chapter 10 Emerging Technologies
- Patient Outcomes Beyond Glucose Control
- Diabetes Technology with Digital Health
- Growing Trend Toward Oral Antidiabetics
- Growing Focus on Accessibility and Affordability of Medicine
- Artificial Pancreas
Chapter 11 M&As and Venture Funding Outlook in the Market
- M&A Analysis
- Lilly's Acquisition of Protomer Technologies
Chapter 12 Competitive Landscape
- Recent Strategic Initiatives, By Major Players in The Market
Chapter 13 Company Profiles
- 77 ELEKTRONIKA KFT.
- ABBOTT
- ALTUCELL
- ASCENSIA DIABETES CARE HOLDINGS AG.
- ASTRAZENECA
- B. BRAUN SE
- BIOCON
- BOEHRINGER INGELHEIM INTERNATIONAL GMBH
- DANAHER
- DEXCOM INC.
- EMBECTA CORP.
- INSULET CORPORATION.
- JOHNSON & JOHNSON SERVICES INC.
- LIFESCAN IP HOLDINGS LLC
- LILLY
- MEDTRONIC
- MENARINI GROUP (A. MENARINI DIAGNOSTICS S.R.L)
- MERCK & CO. INC.
- MERCK KGAA
- NEXTCELL PHARMA AB
- NIPRO
- NOVA BIOMEDICAL
- NOVARTIS AG
- NOVO NORDISK A/S
- ROCHE (F. HOFFMANN-LA ROCHE LTD)
- SANOFI
- TAKEDA PHARMACEUTICAL COMPANY LIMITED.
- TANDEM DIABETES CARE INC.
- TERUMO CORPORATION
- YPSOMED AG
Chapter 14 Appendix
- Government Regulatory Agencies and Professional Organizations
